| Corat Therapeutics–OTHER: investment, 202106 3rd financing round totalling €5.7m? incl private investors from Braunschweig |
2021-06-03 |
| Corat Therapeutics–SEVERAL: investment, 202106 3rd financing round €5.7m? from NBank Capital + private investors |
2021-06-03 |
| Haya Therapeutics–Apollo Health Ventures: investment, 202105 seed financing round totalling CHF18m incl co-investor Apollo HV |
2021-05-20 |
| AMSilk–ER Capital Holdings: investment, 202105 financing round Series C totalling €29m incl new + co-investor ER Capital Holdings |
2021-05-11 |
| OxVax–Evotec: investment, 202104 seed financing round totalling €na incl co-lead investor Evotec |
2021-04-21 |
| Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA |
2021-04-01 |
| Indivumed–Live Wire Strategic Communications: public relations, 202103 service existent by Live Wire |
2021-03-18 |
| Argobio–Evotec: investment, 202103 seed financing round totalling €50m committed capital incl investor Evotec |
2021-03-02 |
| Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test |
2021-01-28 |
| GeneQuine–Brandenburg (govt): grant, 202101 grant €900k from investment bank of federal state Brandenburg |
2021-01-26 |
| GeneQuine–High-Tech Gründerfonds: investment, 202101 financing round Series A totalling €5.4m incl existing + co-investor HTGF |
2021-01-26 |
| GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA |
2021-01-26 |
| GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences |
2021-01-26 |
| GeneQuine–Samum: credit, 202101 convertible loans totalling €2.75m from Pacira BioSciences Inc + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Samum: investment, 202101 financing round Series A totalling €5.4m incl co-investor Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
| LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH |
2021-01-18 |
| LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF |
2021-01-18 |
| LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG |
2021-01-18 |
| LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG |
2021-01-18 |
| Corat Therapeutics–Lower Saxony (govt): investment, 202101 2nd financing round incl existing investor NBank Capital |
2021-01-12 |
| Corat Therapeutics–OTHER: investment, 202101 2nd financing round incl private investors from Braunschweig |
2021-01-12 |
| Corat Therapeutics–SEVERAL: investment, 202101 2nd financing round from NBank Capital + private investors |
2021-01-12 |
| ZytoVision–ArchiMed: investment, 202101 acquisition of majority in Zytomed Systems + ZytoVision + 42 Life Sciences by MED II Fund new holding ZytoMax |
2021-01-12 |
| AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck |
2021-01-07 |
| Novasep–Sartorius: investment, 202101– acquisition €na of Novasep’s chromatography process equipment division by Sartorius ANNOUNCED |
2021-01-06 |
| Cajal Neuroscience–Evotec: investment, 202012 existent Evotec owns 1.82% of voting rights |
2020-12-31 |
| Dark Blue Therapeutics–Evotec: investment, 202012 existent Evotec owns 18.67% of voting rights |
2020-12-31 |
| Mission BioCapital–Evotec: investment, 202012 existent Evotec owns 7.22% of voting rights of Mission BioCapital V LP |
2020-12-31 |
| NephThera–Evotec: investment, 202012 existent Evotec owns 50.00% of voting rights |
2020-12-31 |
| Curexsys–Evotec: investment, 202012 seed financing round totalling €8.2m incl Evotec acquiring 37% equity stake |
2020-12-09 |
| Curexsys–Sartorius: investment, 202012 seed financing round totalling €8.2m incl Sartorius acquiring 21% equity stake |
2020-12-09 |
| Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius |
2020-12-09 |
| Perfood–Boehringer: investment, 202011 financing round Series A totalling €5m incl lead investor Boehringer Ingelheim Venture Fund |
2020-11-30 |
| Perfood–SEVERAL: investment, 202011 financing round Series A €5m led by Boehringer Ingelheim Venture Fund |
2020-11-30 |
| Perfood–UV-Cap: investment, 202011 financing round Series A totalling €5m incl co-investor UV-Cap |
2020-11-30 |
| Perfood–Verve Capital Partners: investment, 202011 financing round Series A totalling €5m incl co-investor investiere |
2020-11-30 |
| Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners |
2020-10-19 |
| Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF |
2020-10-19 |
| Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures |
2020-10-19 |
| Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital |
2020-10-19 |
| Topas Therapeutics–Evotec: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Evotec |
2020-10-19 |
| Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv |
2020-10-19 |
| Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors |
2020-10-19 |
| Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III |
2020-10-19 |
| Iksuda Therapeutics–Univ Göttingen: antibody-drug conjugates, 202010– license excl ww to new class of prodrug payloads for ADCs using PermaLink |
2020-10-13 |
| Prolupin–ECBF: investment, 202010 investment by ECBF in Prolupin GmbH |
2020-10-01 |
| Evotec–Univ Oxford: biobanking, 202009– collab €na granting Evotec access to QUOD biobank for multi-omics analyses for drug discovery |
2020-09-02 |
| Bruker–Univ Utrecht: mass spectromtery, 202008– collab developm of methods using crosslinkg MS for proteomics with Heck lab |
2020-08-07 |
| Quantro Therapeutics–Evotec: drug discovery services, 202007– supply of hit identification services by Evotec |
2020-07-21 |
| Quantro Therapeutics–Evotec: investment, 202007 seed financing round from BIVF + Evotec acquiring equal minority stakes |
2020-07-21 |
| Corat Therapeutics–Lower Saxony (govt): investment, 202006 1st financing round incl existing investor NBank Capital |
2020-06-01 |
| Corat Therapeutics–OTHER: investment, 202006 1st financing round incl private investors from Braunschweig |
2020-06-01 |
| Corat Therapeutics–SEVERAL: investment, 202006 1st financing round from NBank Capital + private investors |
2020-06-01 |
| KI-SIGS project–Germany (govt): grant, 202005– funding €10m from German federal government |
2020-05-27 |
| Exscientia–Evotec: investment, 202005 financing round Series C totalling $60m incl existing + co-investor Evotec |
2020-05-26 |
| Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon |
2020-05-16 |
| OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader |
2020-05-16 |
| Centogene–Ubirch: blockchain technology, 202004 collab announcing secure blockchain solution for storing SARS-CoV-2 test results |
2020-04-17 |
| Evotec–Leon-Nanodrugs: nanoparticle technology, 202004– collab €na strategic partnership incl equity investment |
2020-04-16 |
| Leon-Nanodrugs–Evotec: investment, 202004 financing round Series B incl new + lead investor Evotec |
2020-04-16 |
| Centogene–FTI Consulting: public relations, 202004 service existent by FTI Consulting |
2020-04-15 |
| Evotec–PanCella: iPSC technology, 202004– license €na for use of iACT Stealth Cells + FailSafe technology with EVOcells platform |
2020-04-02 |
| PanCella–Evotec: investment, 202004 minority equity investment €na by Evotec in connection with license agreement |
2020-04-02 |
| Provirex–Hamburg (govt): investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg |
2020-03-31 |
| Provirex–Life Science-Stiftung: investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg |
2020-03-31 |
| Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR |
2020-03-19 |
| Merck (DE)–Dermapharm: investment, 202002–202003 acquisition €na of Merck’s allergy business Allergopharma by Dermapharm Holding SE |
2020-02-19 |
| Temedica–Public Performance: public relations, 202002 service existent by Public Performance |
2020-02-01 |
| Bayer–Evotec: drug discovery services, 201001–202412 collab expansion women’s health €16.5m upfront + research cost + milestones >€330m drugs for PCOS |
2020-01-09 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| Bruker–Adeptrix: MS-based immunoassays, 202101– collab developm BAMS assays on Bruker MALDI-MS systems |
2020-01-06 |
| Aeovian Pharmaceuticals–Evotec: investment, 201912 investment existent Evotec owns 5.83% of voting rights |
2019-12-31 |
| Autobahn Labs–Evotec: investment, 201912 investment existent Evotec owns 33.33% of voting rights |
2019-12-31 |
| Blacksmith Medicines–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights |
2019-12-31 |
| Breakpoint Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 48.6% of voting rights |
2019-12-31 |
| Carrick Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 4.29% of voting rights |
2019-12-31 |
| Celmatix–Evotec: investment, 201912 investment existent Evotec owns 25.02% of voting rights |
2019-12-31 |
| Eternygen–Evotec: investment, 201912 investment existent Evotec owns 24.97% of voting rights |
2019-12-31 |
| Exscientia–Evotec: investment, 201912 investment existent Evotec owns 23.21% of voting rights |
2019-12-31 |
| Fibrocor Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 16% of voting rights of Fibrocor LLP |
2019-12-31 |
| Forge Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights |
2019-12-31 |
| FSHD Unlimited Coop–Evotec: investment, 201912 investment existent Evotec owns 21.12% of voting rights |
2019-12-31 |
| Immunitas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 6.44% of voting rights |
2019-12-31 |
| Topas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 28.44% of voting rights |
2019-12-31 |
| Provecs–NONE: investment, 201912–202001 bankruptcy AG Hamburg 67g IN 290/19 insolvency + dissolution Provecs Medical GmbH |
2019-12-30 |
| Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) |
2019-12-10 |
| Biological Industries (IL)–Sartorius: investment, 201912 acquisition of just over 50% for €45m in cash with option to acquire further 20% |
2019-12-05 |
| Indivumed–Biognosys: MS-based proteomics, 201912– collab integration of HRM MS proteomics data into multi-omics IndivuType cancer database |
2019-12-02 |
| Immunitas Therapeutics–Evotec: investment, 201911 financing round Series A totalling $39m incl co-investor Evotec |
2019-11-21 |
| Evotec–Merck (DE): CRISPR technology, 201911– license to CRISPR IP portfolio from Merck to Evotec |
2019-11-12 |
| Vifor Pharma–Evotec: drug RnD, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w |
2019-11-06 |
| AstraZeneca–BBG/Braun Group: quetiapine fumarate, 201910– acquisition $178m upfront + up to $61m rights to Seroquel/XR in Europe + RU by Cheplapharm |
2019-10-30 |
| Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal |
2019-10-21 |
| Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health |
2019-10-09 |
| Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity |
2019-10-07 |
| Aeovian Pharmaceuticals–Apollo Health Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo HV |
2019-10-03 |
| Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec |
2019-10-03 |
| Takeda–Evotec: drug discovery services, 201909– collab strategic multi-year across multiple indications |
2019-09-24 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
